A Phase II clinical study recently published by Chinese researchers in the British journal The Lancet showed that chimeric antigen receptor T cell (CAR-T) therapy has made important progress in the treatment of malignant solid tumors. Compared with standard therapy, CAR-T therapy significantly prolonged the progression-free survival of patients with advanced cancer. CAR-T is a new type of immunotherapy. Its principle is to separate T lymphocytes from patients and then use genetic engineering technology to give T cells the ability to recognize specific tumor cells and specifically kill them. Currently, this therapy is mainly used to treat certain hematological malignancies.